|
1
|
Augostini A, Wattengel BA, Mergenhagen KA. An Evaluation of Antimicrobial Prophylaxis for Transrectal Prostate Biopsies; a Potential Stewardship Target. Am J Infect Control 2024:S0196-6553(24)00503-0. [PMID: 38782210 DOI: 10.1016/j.ajic.2024.05.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2024] [Revised: 05/15/2024] [Accepted: 05/16/2024] [Indexed: 05/25/2024]
Abstract
BACKGROUND Transrectal prostate biopsy (TRBP) is a common procedure used to obtain a prostate biopsy. Although generally safe, complications may occur including infection. Pre-procedural antimicrobial prophylaxis is recommended to minimize risk of subsequent infection. METHODS This study is a retrospective chart review via the computerized patient record system from January 1, 2018 through February 28, 2022. The study included patients who underwent a TRPB at the Western New York, Syracuse, or Albany Stratton Veterans Affairs Healthcare Systems. RESULTS This study included a total of 932 patients who underwent TRPB. Post-operative infection occurred in 3.2% (n=30) of patients within 14 days of the TRPB. Of the 30 patients who developed an infection, 30% (n=9) resulted in bacteremia. For the 932 patients evaluated, 24 different antibiotic regimens were used, none of which followed guideline recommendations. None of the regimens were found to have an impact on rates of subsequent infection. CONCLUSIONS Results of this study suggest a need for guideline adherence. There was no benefit to using the guideline-discordant regimens as they were not associated with a decreased risk of infection, and in many cases exposed patients to unnecessarily broad and prolonged antibiotic regimens. FUNDING This study was completed without external funding.
Collapse
Affiliation(s)
- Anna Augostini
- Department of Pharmacy, Veterans Affairs Western New York Healthcare System, Buffalo, NY, USA
| | - Bethany A Wattengel
- Department of Pharmacy, Veterans Affairs Western New York Healthcare System, Buffalo, NY, USA
| | - Kari A Mergenhagen
- Department of Pharmacy, Veterans Affairs Western New York Healthcare System, Buffalo, NY, USA.
| |
Collapse
|
|
2
|
Risør BW, Tayyari Dehbarez N, Fredsøe J, Sørensen KD, Pedersen BG. Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 2022; 20:867-880. [PMID: 35934771 PMCID: PMC9596577 DOI: 10.1007/s40258-022-00741-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Accepted: 05/23/2022] [Indexed: 06/15/2023]
Abstract
OBJECTIVE This study evaluated the cost effectiveness of using Stockholm 3 (STHLM3) testing compared to the prostate-specific antigen (PSA) test in the diagnostic pathway for prostate cancer. METHODS We created a decision tree model for PSA (current standard) and STHLM3 (new alternative). Cost effectiveness was evaluated in a hypothetical cohort of male individuals aged 50-69 years. The study applied a Danish hospital perspective with a time frame restricted to the prostate cancer diagnostic pathway, beginning with the initial PSA/STHLM3 test, and ending with biopsy and histopathological diagnosis. Estimated values from the decision-analytical model were used to calculate the incremental cost-effectiveness ratio. Deterministic and probabilistic sensitivity analyses were conducted to test the robustness of the base-case analysis. RESULTS The model-based analysis revealed that STHLM3 testing was more effective than the PSA, but also more costly, with an incremental cost-effectiveness ratio of €511.7 (95% credible interval, 359.9-674.3) for each additional correctly classified individual. In the deterministic sensitivity analysis, variations in the cost of STHLM3 had the greatest influence on the incremental cost-effectiveness ratio. In the probabilistic sensitivity analysis, all iterations were positioned in the north-east quadrant of the incremental cost-effectiveness scatterplot. At a willingness to pay of €700 for an additional correctly classified individual, STHLM3 had a 100% probability of being cost effective. CONCLUSIONS Compared to the PSA test as the initial testing modality in the prostate cancer diagnostic workup, STHLM3 testing showed improved incremental effectiveness, however, at additional costs. The results were sensitive to the cost of the STHLM3 test; therefore, a lower cost of the STHLM3 test would improve its cost effectiveness compared with PSA tests.
Collapse
Affiliation(s)
- Bettina Wulff Risør
- DEFACTUM, Central Denmark Region, Olof Palmes Allé 15, 8200, Aarhus N, Denmark.
- Danish Center for Healthcare Improvements (DCHI), Aalborg University, 9220, Aalborg, Denmark.
- Nordic Institute of Health Economics, 8000, Aarhus C, Denmark.
| | - Nasrin Tayyari Dehbarez
- DEFACTUM, Central Denmark Region, Olof Palmes Allé 15, 8200, Aarhus N, Denmark
- Danish Center for Healthcare Improvements (DCHI), Aalborg University, 9220, Aalborg, Denmark
| | - Jacob Fredsøe
- Department of Molecular Medicine (MOMA), Aarhus University Hospital, 8200, Aarhus N, Denmark
- Department of Clinical Medicine, Aarhus University, 8200, Aarhus N, Denmark
| | - Karina Dalsgaard Sørensen
- Department of Molecular Medicine (MOMA), Aarhus University Hospital, 8200, Aarhus N, Denmark
- Department of Clinical Medicine, Aarhus University, 8200, Aarhus N, Denmark
| | - Bodil Ginnerup Pedersen
- Department of Clinical Medicine, Aarhus University, 8200, Aarhus N, Denmark
- Department of Radiology, Aarhus University Hospital, 8200, Aarhus N, Denmark
| |
Collapse
|
|
3
|
Comparison of Fluoroquinolones and Other Antibiotic Prophylaxis Regimens for Preventing Complications in Patients Undergoing Transrectal Prostate Biopsy. Antibiotics (Basel) 2022; 11:antibiotics11030415. [PMID: 35326878 PMCID: PMC8944856 DOI: 10.3390/antibiotics11030415] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2022] [Revised: 03/16/2022] [Accepted: 03/18/2022] [Indexed: 01/26/2023] Open
Abstract
Our study aimed to compare the incidence of infective complications after transrectal ultrasound-guided prostate biopsy (TRUSBx) when adopting different antimicrobial prophylaxis regimens. A multi-institutional cohort of 1150 patients who underwent TRUSBx was retrospectively analyzed. Procedures were performed between 2017 and 2019 (before and after the EMA warning about the use of fluoroquinolones for the antibiotic prophylaxis of patient candidates to TRUSBx). The primary endpoint was the occurrence of infective complications, including sepsis and/or fever. The population was stratified according to the antibiotic prophylaxis adopted: fluoroquinolones (levofloxacin, ciprofloxacin, prulifloxacin), cephalosporins (cefixime, ceftriaxone) or trimethoprim/sulfamethoxazole. Univariable and multivariable binomial logistic regression models were used to assess the odds ratio (OR) with 95% confidence interval (CI) testing of the risk of infective complication after adjusting for each prebiopsy covariate. In total, 478 (41.6%) patients received fluoroquinolone-based prophylaxis. Among these, 443 (38.5%), 25 (2.2%) and 10 (0.9%) patients received levofloxacin prophylaxis, ciprofloxacin and prulifloxacin, respectively while 14.6% received cefixime, 20.7% received the comedication of ceftriaxone/fosfomycin and 23.1% received trimethoprim/sulfamethoxazole. The trimethoprim/sulfamethoxazole and fluoroquinolone regimens were significantly associated with a lower risk of infective complications (OR 0.15, 95% CI 0.03−0.48, p = 0.003 and OR 0.17, 95% CI 0.06−0.43, p < 0.001, respectively). The ceftriaxone/fosfomycin (OR 0.21, 95% CI 0.04−0.92, p = 0.04) and fluoroquinolone (OR 0.07, 95% CI 0.00−0.70, p = 0.048) prophylaxis were associated with a lower risk of infective sequelae. Fluoroquinolone-based prophylaxis was associated with a lower risk of infective complications after TRUSBx compared to other prophylaxis regimens although its clinical application was recently forbidden by European Medical Agency restrictions.
Collapse
|
|
4
|
Acosta H, Sadahira T, Sekito T, Maruyama Y, Iwata T, Araki M, Ogawa K, Tsuboi I, Wada K. Post-prostate biopsy acute bacterial prostatitis and screening cultures using selective media: An overview. Int J Urol 2022; 29:486-493. [PMID: 35144308 DOI: 10.1111/iju.14824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2021] [Revised: 01/09/2022] [Accepted: 02/01/2022] [Indexed: 11/30/2022]
Abstract
The development of several culture media and the availability to isolate and treat pathogens prior to a surgical procedure give us the ability to minimize treatment-related complications, and ultimately results in better outcomes for patients and avoidance of unwanted post-procedure inpatient admissions. In the last decade, an increasing incidence of multidrug-resistant Escherichia coli, especially extended-spectrum beta-lactamase-producing E. coli and fluoroquinolone-resistant pathogens, has been reported. These resistant species frequently colonize the rectal flora and gain access to the systemic circulation via the rectal plexus following a prostate biopsy. The bacteria can eventually lead to life-threatening complications, which is especially important in high-risk patients with multiple co-morbidities. Previously published studies have focused on the isolation of these pathogens with selective media before an invasive procedure and the potential benefits of incorporating the use of selective media as a mandatory pre-operative step. This preventive measure will allow us to offer a tailored prophylactic treatment that benefits patients and reduces the economic burden for the hospital.
Collapse
Affiliation(s)
- Herik Acosta
- Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
| | - Takuya Sadahira
- Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
| | - Takanori Sekito
- Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
| | - Yuki Maruyama
- Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
| | - Takehiro Iwata
- Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
| | - Motoo Araki
- Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
| | - Kohei Ogawa
- Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan
| | - Ichiro Tsuboi
- Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan
| | - Koichiro Wada
- Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan
| |
Collapse
|
|
5
|
Ankrah D, Owusu H, Aggor A, Osei A, Ampomah A, Harrison M, Nelson F, Aboagye GO, Ekpale P, Laryea J, Selby J, Amoah S, Lartey L, Addison O, Bruce E, Mahungu J, Mirfenderesky M. Point Prevalence Survey of Antimicrobial Utilization in Ghana's Premier Hospital: Implications for Antimicrobial Stewardship. Antibiotics (Basel) 2021; 10:antibiotics10121528. [PMID: 34943740 PMCID: PMC8698913 DOI: 10.3390/antibiotics10121528] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Revised: 12/08/2021] [Accepted: 12/08/2021] [Indexed: 12/19/2022] Open
Abstract
The first comprehensive point prevalence survey at the Korle Bu Teaching Hospital (KBTH) was performed as part of the 2019 Global Point Prevalence Survey (Global-PPS) on antimicrobials. The aim was to establish a PPS baseline for the whole hospital and to identify required stewardship interventions. The PPS was conducted over three days in June 2019 using the GLOBAL-PPS standardized method for surveillance of antimicrobial utilization in hospitals to evaluate antimicrobial prescribing. In all, 988 patients were admitted to 69 wards. Overall antimicrobial prevalence was 53.3%. More community-acquired infections (CAI) were treated empirically compared to health-care associated infections (94.0% vs. 86.1% respectively, p = 0.002). Main indications for prescribing antimicrobials were pneumonia (18.4%), skin and soft tissue infections (11.4%) and sepsis (11.1%). Among antimicrobials, systemic antibiotics accounted for 83.5%, of which amoxicillin with beta-lactam inhibitor (17.5%), metronidazole (11.8%) and ceftriaxone (11.5%) dominated. Guideline compliance was 89.0%. Stop/review dates were completed in 33.4% and documented reason was recorded in 53.0% of all prescriptions. If the findings in this PPS can be addressed antimicrobial stewardship at the KBTH stands to improve significantly.
Collapse
Affiliation(s)
- Daniel Ankrah
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
- Correspondence:
| | - Helena Owusu
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Asiwome Aggor
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Anthony Osei
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Agneta Ampomah
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Mark Harrison
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Frempomaa Nelson
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Grace Owusu Aboagye
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Priscilla Ekpale
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Jennifer Laryea
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Julia Selby
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Serwaa Amoah
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Linda Lartey
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Okaikor Addison
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Elizabeth Bruce
- Korle-Bu Teaching Hospital, Accra GA-221-1570, Ghana; (H.O.); (A.A.); (A.O.); (A.A.); (M.H.); (F.N.); (G.O.A.); (P.E.); (J.L.); (J.S.); (S.A.); (L.L.); (O.A.); (E.B.)
| | - Joyce Mahungu
- North Middlesex University Hospital NHS Trust, London N18 1QX, UK; (J.M.); (M.M.)
| | | |
Collapse
|
|
6
|
Tops SCM, Huis AMP, Trompers W, Oerlemans AJM, Sedelaar JPM, Kolwijck E, Wertheim HFL, Hulscher MEJL. Acceptability of innovative culture-based antibiotic prophylaxis strategies: a multi-method study on experiences regarding transrectal prostate biopsy. JAC Antimicrob Resist 2021; 3:dlab161. [PMID: 34806004 PMCID: PMC8599774 DOI: 10.1093/jacamr/dlab161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Accepted: 09/27/2021] [Indexed: 11/12/2022] Open
Abstract
Background The acceptability of innovative medical strategies among healthcare providers and patients affects their uptake in daily clinical practice. Objectives To explore experiences of healthcare providers and patients with culture-based antibiotic prophylaxis in transrectal prostate biopsy with three swab-screening scenarios: self-sampling at home, self-sampling in the hospital and sampling by a healthcare provider. Methods We performed focus group interviews with urologists and medical microbiologists from 11 hospitals and six connected clinical microbiological laboratories. We used Flottorp's comprehensive checklist for identifying determinants of practice to guide data collection and analysis. The experiences of 10 laboratory technicians from five laboratories and 452 patients from nine hospitals were assessed using a questionnaire. Results Overall, culture-based prophylaxis strategies were experienced as feasible in daily clinical practice. None of the three swab-screening scenarios performed better. For urologists (n = 5), implementation depended on the effectiveness of the strategy. In addition, it was important to them that the speed of existing oncology care pathways is preserved. Medical microbiologists (n = 5) and laboratory technicians (n = 8) expected the strategy to be fairly easy to implement. Patients (n = 430; response rate 95.1%) were generally satisfied with the screening scenario presented to them. To meet the various patients' needs and preferences, multiple scenarios within a hospital are probably needed. Conclusions This multi-method study has increased our understanding of the acceptability of culture-based prophylaxis strategies in prostate biopsy, which can help healthcare providers to offer high-quality patient-centred care. The strategy seems relatively straightforward to implement as overall acceptance appears to be high.
Collapse
Affiliation(s)
- Sofie C M Tops
- Department of Medical Microbiology, Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Anita M P Huis
- Scientific Center for Quality of Healthcare (IQ healthcare), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Willeke Trompers
- Scientific Center for Quality of Healthcare (IQ healthcare), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Anke J M Oerlemans
- Scientific Center for Quality of Healthcare (IQ healthcare), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - J P Michiel Sedelaar
- Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Eva Kolwijck
- Department of Medical Microbiology, Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.,Department of Medical Microbiology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands
| | - Heiman F L Wertheim
- Department of Medical Microbiology, Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Marlies E J L Hulscher
- Scientific Center for Quality of Healthcare (IQ healthcare), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
|
7
|
Shigemura K, Fujisawa M. Prevention and management of infectious complications in prostate biopsy: A review. Int J Urol 2021; 28:714-719. [PMID: 33966298 DOI: 10.1111/iju.14572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Accepted: 03/18/2021] [Indexed: 11/27/2022]
Abstract
Prostate biopsies are common procedures for urologists, performed in order to detect and diagnose prostate cancer. Procedures continue to evolve, for instance, recently there has been an increase in the use of the transperineal approach, and the emergence of antibiotic-resistant bacteria has become a challenge. This review examines the recent prostate biopsy literature as well as the guidelines of three urological associations. We review the recent literature, including our own recent studies, and the Japanese Urological Association, European Association of Urology and American Urological Association guidelines, and summarize the current recommendations regarding the prevention of infectious complications that can occur after prostate biopsy, including the use of antimicrobial agents, and the management and treatment of such complications. Current recommendations include single-dose or 1-day use of oral quinolones for infection control, along with consideration of high-risk patients with diabetes, steroid use, large prostates, or high residual urine volume for instance. Targeted therapies based on the results of rectal swabs carried out prior to transrectal prostate biopsy, which can provide better inhibitory data with regard to post-prostate biopsy infectious complications, can also be considered. In conclusion, oral quinolones for low-risk patients and targeted therapies for high-risk patients are recommended when using a transrectal approach to prostate biopsy, and oral quinolones are recommended when using a transperineal approach. Further randomized controlled trials are necessary to draw more definitive conclusions.
Collapse
Affiliation(s)
| | - Masato Fujisawa
- Department of Urology, Kobe University Hospital, Kobe, Hyogo, Japan
| |
Collapse
|
|
8
|
A Systematic Review and Meta-Analysis of Methods Used to Reduce Infectious Complications Following Transrectal Prostate Biopsy. Urology 2020; 144:21-27. [DOI: 10.1016/j.urology.2020.06.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 05/27/2020] [Accepted: 06/07/2020] [Indexed: 11/21/2022]
|
|
9
|
Infectious complications of prostate biopsy: winning battles but not war. World J Urol 2020; 38:2743-2753. [PMID: 32095882 DOI: 10.1007/s00345-020-03112-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Accepted: 01/30/2020] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Prostate biopsy is a standard tool for diagnosing prostate cancer, with more than 4 million procedures performed worldwide each year. Infectious complications and economic burden are reportedly rising with continued use of trans-rectal ultrasound-guided biopsy, despite the transperineal approach being associated with less infectious complications. OBJECTIVE AND METHODS In this review, the contemporary literature on pathophysiology, epidemiology, risk factors, causative organisms and emerging approaches for prevention of infectious complications are outlined. RESULTS Management of infectious complications after TRUSB has caused significant financial burden on health systems. The most frequent causative agents of infectious complications after prostate biopsy are Gram-negative bacilli are particularly concerning in the era of antibiotic resistance. Increasing resistance to fluoroquinolones and beta-lactam antibiotics has complicated traditional preventive measures. Patient- and procedure-related risk factors, reported by individual studies, can contribute to infectious complications after prostate biopsy. CONCLUSIONS Recent literature shows that the transrectal ultrasound-guided prostate biopsy results in higher infectious complication rate than the transperineal prostate biopsy. NAATs, recently introduced technique to detect FQr may detect all antibiotic-resistant rectal microbiota members-included MDRs-although the technique still has limitations and economical burdens. Transient solutions are escalating antibiotic prophylaxis and widening the indications for TPB.
Collapse
|